Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: Discordant effects on minimal erythema dose and sunburn cell formation

British Journal of Dermatology

Volumn 151, Issue 2, 2004, Pages 458-464

  Cummins, D L ^a   Gaspari, A A ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic cutaneous lupus erythematosus; Discoid lupus; Photoprotection; Thalidomide

Indexed keywords

SINGLE STRANDED DNA; THALIDOMIDE;

ADULT; APOPTOSIS; ARTICLE; CASE REPORT; CONTROLLED STUDY; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; NICK END LABELING; PRIORITY JOURNAL; RADIATION INJURY; SKIN BIOPSY; SKIN DISEASE; SUNBURN; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET IRRADIATION;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN SITU NICK-END LABELING; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RADIATION DOSAGE; RADIATION-PROTECTIVE AGENTS; SKIN; SUNBURN; THALIDOMIDE; ULTRAVIOLET RAYS;

EID: 4544302723     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06117.x     Document Type: Article

References (39)

1. Fiet H. Light as an exciting agent in lupus erythematosus and other dermatoses. J Med Soc NJ 1927; 24: 226-9.
2. Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 195-212.
3. Sontheimer RD. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem Photobiol 1996; 63: 583-94.
4. Lehmann P, Holzle E, Kind P et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Oermatol 1990; 22; 181-7.
5. Everett MA, Olson RL. Response of cutaneous lupus erythematosus to ultraviolet light. J Invest Oermatol 1965; 44: 133-9.
6. Hasan T, Nyberg F, Stephansson E et al. Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivity and clinical findings. Br J Dermatol 1997; 136; 699-70.
7. Wolska H, Blaszczyk M, Jablonska S. Phototests in patients with various forms of lupus erythematosus. Int J Dermatol 1989; 28: 98-103.
8. Sjolin-Forsberg G, Berne B, Eggelte TA, Karlsson-Parra A. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol (Stockh) 1995; 75: 228-31.
9. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11: 71-81.
10. Tseng S, Pak G, Washenik K et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-79.
11. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487-93.
12. Crouch RB, Foley PA, Ng JC, Baker CS. Thalidomide experience of a major Australian teaching hospital. Australas J Dermatol 2002; 43: 278-84.
13. Lovell CR, Hawk JL, Calnan CD, Magnus IA. Thalidomide in actinic prurigo. Br J Dermatol 1983; 108: 467-71.
14. Grabczyska SA, Hawk JL. Managing PLE and actinic prurigo. Practitioner 1997; 241: 74, 77, 79.
15. Gu H, Chang B, Qian H, Li G. A clinical study on severe hydroa vacciniforme. Chin Med J (Engl) 1996; 109: 645-7.
16. Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33: 837-8.
17. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814-19.
18. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980; 269: 275-80.
19. Moreira AL, Sampaio EP, Zmuidzinas A et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
20. Murphy G, Young AR, Wulf HC et al. The molecular determinants of sunburn cell formation. Exp Dermatol 2001; 10: 155-60.
21. Rathjen DA, Cowan K, Furphy LJ, Aston R. Antigenic structure of human tumour necrosis factor: recognition of distinct regions of TNF-alpha by different tumour cell receptors. Mol Immunol 1991; 28: 79-86.
22. Duong DJ, Spigel GT, Moxley RT III, Gaspari AA. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079-87.
23. Elenitsas R, Belle P, Elder D. Laboratory methods. In: Lever's Histopathology of the Skin (Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, eds), 8th edn, Philadelphia: Lippincott-Raven, 1997: 51-60.
24. Gavrieli Y, Sherman Y, Ben Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
25. Kock A, Schwarz T, Kirnbauer R et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 1990; 172: 1609-14.
26. 2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1996; 271: 21793-7.
27. Noguchi T, Shimazawa R, Nagasawa K, Hashimoto Y. Thalidomide and its analogues as cyclooxygenase inhibitors. Bioorg Med Chem Lett 2002; 12: 1043-6.
28. Fujita J, Mestre JR, Zeldis JB et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001; 7: 3349-55.
29. Zhuang L, Wang B, Sauder DN. Molecular mechanism of ultraviolet-induced keratinocyte apoptosis. J Interferon Cytokine Res 2000; 20: 445-54.
30. Schwarz A, Bhardwaj R, Aragane Y et al. Ultraviolet-B-induced apoptosis of keratinocytes: evidence for partial involvement of tumor necrosis factor-alpha in the formation of sunburn cells. J Invest Dermatol 1995; 104: 922-7.
31. Schwarz A, Mahnke K, Luger TA, Schwarz T. Pentoxifylline reduces the formation of sunburn cells. Exp Dermatol 1997; 6: 1-5.
32. Simics E, Mahunka M, Horkay I et al. Effect of pentoxifylline on sunburn cell formation in a novel supravital human skin model. Photodermatol Photoimmunol Photomed 2000; 16: 278-80.
33. Rosette C, Karin M. Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 1996; 274: 1194-7.
34. Kulms D, Schwarz T. Independent contribution of three different pathways to ultraviolet-B-induced apoptosis. Biochem Pharmacol 2002; 64: 837-41.
35. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-7.
36. Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-30.
37. Fisher GJ, Datta SC, Talwar HS et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 1996; 379: 335-9.
38. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994; 10: 405-55.
39. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30.